Skip to main content
Contact Us
Subscribe
E-Edition
75°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tiziana Life Sciences Ltd
(NQ:
TLSA
)
0.7028
-0.0422 (-5.66%)
Streaming Delayed Price
Updated: 3:57 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Tiziana Life Sciences Ltd
< Previous
1
2
3
4
5
Next >
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light
September 12, 2023
Tiziana Life Sciences Ltd.
Via
Benzinga
Exposures
Product Safety
Tiziana Life Sciences' Alzheimer's treatment validated in new study
September 12, 2023
--News Direct--
Via
News Direct
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...
Via
Benzinga
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision
August 16, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 15, 2023
Via
Benzinga
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 15, 2023
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.
Via
Benzinga
Why Tiziana Life Sciences Stock (TLSA) Is Climbing
August 15, 2023
Tiziana Life Sciences, Ltd (NASDAQ: TLSA) shares are trading higher Tuesday after the company announced that the FDA has cleared the Investigational New Drug (IND) application for intranasal foralumab...
Via
Benzinga
Exposures
Product Safety
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
August 15, 2023
--News Direct--
Via
News Direct
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 15, 2023
Via
Benzinga
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
August 09, 2023
--News Direct--
Via
News Direct
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
August 08, 2023
Tiziana Life Sciences, Inc.
Via
Benzinga
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
August 04, 2023
--News Direct--
Via
News Direct
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
August 03, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 01, 2023
Via
Benzinga
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
July 27, 2023
--News Direct--
Via
News Direct
Exposures
Product Safety
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)
July 10, 2023
Tiziana Life Sciences (NASDAQ: TLSA) is a biotechnology company establishing itself in a cutting-edge position in the market with its breakt
Via
Benzinga
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company?
June 15, 2023
Company Moves Ahead With Drug Development
Via
Benzinga
Tiziana's Foralumab Shown To Reduce Microglial Activation In MS Patients; Phase 2a Trial To Begin In Q3 2023
June 06, 2023
Tiziana Life Sciences Ltd.
Via
Benzinga
DeSantis Rule Shields Musk's SpaceX From Liability
May 26, 2023
Florida Gov. Ron DeSantis signed a new bill Thursday providing additional liability protections to space companies like Elon Musk's SpaceX.
Via
Investor's Business Daily
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
May 05, 2023
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
Via
News Direct
Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial
April 21, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer’s Disease in Q2 2023.
Via
Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 25, 2023
Gainers
Via
Benzinga
EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients
April 13, 2023
Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID. What Happened: The work is supported by foralumab's well-established role in de-activating microglia...
Via
Benzinga
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
April 12, 2023
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...
Via
Benzinga
Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
March 29, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of...
Via
Benzinga
7 Thrilling Stocks to Buy for Aggressive Investors
March 06, 2023
Sometimes you need to be aggressive to unlock the best returns for your portfolio. Just be smart when looking for the best stocks to buy.
Via
InvestorPlace
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
February 09, 2023
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
Via
News Direct
Tesla HODLs Bitcoin — But Sticks To Dogecoin-Only Crypto Payments Policy
January 26, 2023
Electric car maker Tesla Inc (NASDAQ: TLSA) continues to hold on to Bitcoin (CRYPTO: BTC) but only accepts Dogecoin (CRYPTO:
Via
Benzinga
Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis
January 03, 2023
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.